Innovent Biologics, Inc. (HKG:1801)
Hong Kong
· Delayed Price · Currency is HKD 52.40
+0.70 (1.35%)
May 9, 2025, 4:08 PM HKT
Innovent Biologics Revenue
In the year 2024, Innovent Biologics had annual revenue of 9.42B CNY with 51.82% growth. Innovent Biologics had revenue of 5.47B in the half year ending December 31, 2024, with 136.09% growth.
Revenue
9.42B CNY
Revenue Growth
+51.82%
P/S Ratio
8.61
Revenue / Employee
1.66M CNY
Employees
5,659
Market Cap
86.36B HKD
Revenue Chart
* This company reports financials in CNY.
Revenue History
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| BeiGene | 32.49B |
| Hansoh Pharmaceutical Group Company | 13.05B |
| JD Health International | 61.89B |
| WuXi Biologics | 19.87B |
| Alibaba Health Information Technology | 31.39B |
| Akeso | 2.26B |
| Sichuan Kelun-Biotech Biopharmaceutical | 2.06B |
| Sino Biopharmaceutical | 30.72B |
Innovent Biologics News
- 2 days ago - Bispecific vs. Bispecific: Innovent Announces First Patient Dosed in the Phase 2 Clinical Study ... - GuruFocus
- 2 days ago - Bispecific vs. Bispecific: Innovent Announces First Patient Dosed in the Phase 2 Clinical Study of Efdamrofusp Alfa (IBI302), a First-in-class Anti-VEGF and Anti-Complement Bispecific Fusion Protein for the Treatment of Diabetic Macular Edema - PRNewsWire
- 3 days ago - Innovent Announces Oral Presentation of Full Phase 2 Clinical Data for Efdamrofusp Alfa (IBI302), First-in-class anti-VEGF/complement Bispecific Fusion Protein at ARVO 2025 - PRNewsWire
- 9 days ago - Innovent Announces First Patient Dosed in Phase 1 Study of IBI3020, Global First-in-class Dual Payload CEACAM5 ADC, in Patients with Advanced Malignancies - PRNewsWire
- 11 days ago - Innovent Biologics Inc (IVBIY) Showcases Groundbreaking Preclinical Data at AACR 2025 | IVBIY ... - GuruFocus
- 11 days ago - 2025 AACR | Innovent Presents Preclinical Data of Multiple Novel Molecules including Bispecific ... - GuruFocus
- 11 days ago - 2025 AACR | Innovent Presents Preclinical Data of Multiple Novel Molecules including Bispecific and Tri-specific Antibodies and Bispecific ADCs - PRNewsWire
- 13 days ago - Innovent Biologics Inc (IVBIY) Secures NMPA Approval for Limertinib as First-Line Treatment for ... - GuruFocus